— Mixed results in seven-study scoping review
The jury is still out as to whether diabetes is a risk factor for post-acute sequelae of COVID-19 (PASC), a researcher reported.
In a scoping review of seven studies, three (43%) concluded that diabetes was indeed a “potent” risk factor for developing long COVID following infection, according to Jessica L. Harding, PhD, of Emory University School of Medicine in Atlanta.
Read more in MedPage Today.
NEW YORK – Taking organ donor and recipient genetics into consideration — via a polygenic risk score (PRS) — may help identify individuals at risk of developing diabetes after a solid organ transplant.
“Our study demonstrates the importance, and the potential application, of PRS in solid organ transplantation,” co-first and corresponding author Abraham Shaked, a researcher at the University of Pennsylvania’s Penn Transplant Institute, and his coauthors wrote in Nature Medicine on Thursday. Read the story in GenomeWeb here.
Adults with type 2 diabetes and a higher BMI may have an increased risk for diabetic kidney disease, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.
In findings from a generalized summary Mendelian randomization using 56 BMI-associated single nucleotide polymorphisms instrument variables, increasing BMI was linked to an increased risk for diabetic nephropathy and a lower estimated glomerular filtration rate, with the effects most pronounced among women. Read more.
Even if you did not have diabetes before, you may develop diabetes after an organ transplant. This type of diabetes is called “new-onset diabetes” after transplant. It is also called “NODAT” for short. New-onset diabetes can occur as a side effect of the medications that you need to prevent rejection of your new organ. Read more.
“Adults with type 2 diabetes and end-stage renal disease requiring dialysis benefitted from an artificial pancreas in a small, randomized crossover trial.
Patients using a fully automated closed loop system spent a longer amount of time in target glucose range versus those using standard insulin therapy (52.8% vs 37.7%, respectively, P<0.001), reported Charlotte Boughton, MD, PhD, of University of Cambridge Metabolic Research Laboratories in England, and colleagues.”
Read more, here.
“FDA has approved Kerendia (finerenone) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.
Diabetes is the leading cause of chronic kidney disease and kidney failure in the United States. Chronic kidney disease occurs when the kidneys are damaged and cannot filter blood normally. Because of defective filtering, patients can have complications related to fluid, electrolytes (minerals required for many bodily processes), and waste build-up in the body. Chronic kidney disease sometimes can progress to kidney failure. Patients also are at high risk of heart disease.”
Read the full report by the FDA, here.
Some of the most favorable alternative sources for diabetes cell replacement therapy are human stem cells. However, a critical challenge has been finding a safe, effective means to introduce replacement cells that normalize blood sugar levels without triggering the body’s natural immune response.
Researchers at the Washington University School of Medicine in St. Louis, MO, and Cornell University in Ithaca, NY, have collaborated to develop a tiny implant that successfully delivers insulin-secreting cells, or beta cells, into mice with diabetes, without the need for immunosuppressive drug treatment.
Read more, here.
“There is promising news for patients with chronic kidney disease (CKD) and type 2 diabetes—a serious medical condition that is also known as diabetic kidney disease.
Clinical trials have shown finerenone, a pill taken once per day, may prevent diabetic kidney disease from getting worse. Worsening diabetic kidney disease can cause heart problems and kidney failure.
Diabetes damages small blood vessels throughout the body, affecting the kidneys as well as other organs and tissues including skin, nerves, muscles, intestines, and the heart. More than 1 out of 4 adults with diabetes will eventually develop kidney disease, and in the US alone, millions of people already have diabetic kidney disease.
People with type 2 diabetes and kidney disease are three times more likely to die of heart-related causes than those with type 2 diabetes alone. Diabetes is also the leading cause of kidney failure, accounting for 44% of new cases.”
Read the full post, here.
“A new guideline from the Kidney Disease: Improving Global Outcomes (KDIGO) group addressing issues around diabetes management in patients with chronic kidney disease (CKD) has just been published in synopsis form in Annals of Internal Medicine.
The full guideline, including 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD, was published last month in Kidney International and on the KDIGO website.
More than 40% of people with diabetes develop CKD, and a significant number develop kidney failure requiring dialysis or transplant. This is the first guidance from KDIGO to address the comorbidity.”
Read more, here.